Table 2.
Rate ratios (RR) for developing breast cancer in relation to tertiles of plasma levels of inflammation biomarkers.
| Tertile I | Tertile II | Tertile III | P trend | Continuous (for 1 SD* increase) | |
|---|---|---|---|---|---|
| C-reactive protein | |||||
| Range, ng/ml | 0.005–2045.97 | 2047.44–5462.91 | 5469.28–164231.26 | ||
| Cases/Controls | 120/117 | 110/117 | 121/117 | ||
| RR1 (95% CI**) | 1 | 0.89 (0.62–1.289 | 1.06 (0.70–1.59) | 0.843 | 0.91 (0.76–1.09) |
| RR2 (95% CI) | 1 | 0.95 (0.65–1.38) | 1.15 (0.75–1.76) | 0.553 | 0.91 (0.76–1.08) |
| TNF-α | |||||
| Range, pg/ml | 0.009–0.6 | 0.605–1.63 | 1.64–110.51 | ||
| Cases/Controls | 117/119 | 89/115 | 145/117 | ||
| RR1 (95% CI) | 1 | 0.83 (0.50–1.38) | 1.36 (0.81–2.30) | 0.093 | 1.25 (0.97–1.61) |
| RR2 (95% CI) | 1 | 0.84 (0.50–1.43) | 1.36 (0.79–2.34) | 0.105 | 1.27 (0.97–1.65) |
| Interleukin-6 | |||||
| Range, pg/ml | 0.06–1.64 | 1.65–3.39 | 3.41–81.97 | ||
| Cases/Controls | 110/117 | 115/117 | 126/117 | ||
| RR1 (95% CI) | 1 | 1.15 (0.71–1.84) | 1.40 (0.80–2.45) | 0.224 | 1.15 (0.95–1.39) |
| RR2 (95% CI) | 1 | 1.22 (0.75–1.98) | 1.58 (0.89–2.82) | 0.114 | 1.17 (0.96–1.43) |
| Leptin | |||||
| Range, pg/ml | 222.82–4662.34 | 4672.62–8946.89 | 8949.08–26775.92 | ||
| Cases/Controls | 126/117 | 112/117 | 113/117 | ||
| RR1 (95% CI) | 1 | 0.81 (0.54–1.21) | 0.83 (0.52–1.34) | 0.440 | 0.96 (0.77–1.19) |
| RR2 (95% CI) | 1 | 0.78 (0.51–1.19) | 0.83 (0.51–1.37) | 0.486 | 0.98 (0.78–1.22) |
| Adiponectin | |||||
| Range, pg/ml | 976575.38–6567600 | 6590400–10776000 | 10778000–60520000 | ||
| Cases/Controls | 125/117 | 125/117 | 101/117 | ||
| RR1 (95% CI) | 1 | 0.98 (0.67–1.43) | 0.72 (0.48–1.09) | 0.126 | 0.88 (0.74–1.04) |
| RR2 (95% CI) | 1 | 1.05 (0.71–1.55) | 0.73 (0.48–1.11) | 0.155 | 0.89 (0.74–1.05) |
*Standard deviation; **Confidence interval
1Adjusted for age and BMI.
2Further adjusted for family history of breast cancer, age at menarche, parity, oral contraceptive use, smoking status, education, and alcohol consumption.